Lanadut

Dutasteride, the active ingredient in Lanadut, is a 5-alpha-reductase inhibitor presented as an oral dosage form for oral use. It treats benign prostatic hyperplasia in men and is also employed off‑label for male pattern hair loss.

GNH USA supplies Lanadut as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Dutasteride acts on the hormonal pathway that drives prostate enlargement and androgen‑related hair loss. - Benign prostatic hyperplasia (BPH): reduces prostate volume and improves urinary flow in men. - Male pattern hair loss (off‑label): may slow hair thinning and promote regrowth of scalp hair.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Decreased libido: reduced sexual desire. - Erectile dysfunction: difficulty achieving or maintaining an erection. - Ejaculation disorders: decreased volume or pain. - Breast tenderness or enlargement: mild swelling of male breast tissue. - Decreased semen volume: reduced ejaculate amount. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Breast cancer: rare occurrence of malignant breast tissue. - Liver enzyme elevation: signs of hepatic dysfunction. - Severe hypotension: marked drop in blood pressure, especially when combined with certain antihypertensives. - Persistent sexual dysfunction: lasting loss of sexual function after discontinuation.

Patients should be aware of several safety considerations before starting therapy. - Monitor PSA levels: regular testing to assess prostate health. - Evaluate liver function: baseline and periodic liver enzyme checks. - Avoid use in women of childbearing potential: contraindicated due to teratogenic risk. - Assess cardiovascular status: caution in patients with low blood pressure. - Counsel about potential sexual side effects: discuss possible changes in libido and erectile function. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Dutasteride may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase dutasteride exposure. - Alpha‑blockers (e.g., tamsulosin): combined use can cause symptomatic hypotension. - Warfarin: potential increase in INR and bleeding risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce dutasteride effectiveness. - Other 5‑alpha‑reductase inhibitors (e.g., finasteride): additive hormonal effects. - Antiplatelet agents (e.g., aspirin, clopidogrel): monitor for enhanced bleeding tendency.